[27PS2-pm] Therapeutic drug monitoring (TDM) and administration plans/Pharmacotherapies (Personalized therapies)

[27PS2-pm06S] Plasma concentrations of osimertinib and treatment progress in patients with non-small cell lung cancer

○Sae Nakahara¹, Nao Komizo¹, Mizuki Yamazaki^1,2, Chisato Nanba¹, Chiemi Hirose², Hirotoshi Iihara^1,2, Yuto Yamada^1,2, Komei Yanase³, Yasushi Ohno³, Kenichiro Todoroki⁴, Shuji Yamashita¹, Akio Suzuki^1,2, Hideki Hayashi^1,2 (1. Gifu Pharm. Univ., 2. Dpt. of Pharm., Gifu Univ. Hosp., 3. Dpt. of Respir. Med., Gifu Univ. Hosp., 4. Sch. of Pharm. Sci., Univ. of Shizuoka)